Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised controlled trial programme

Next Previous
X
Search
Trial Profile

Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised controlled trial programme

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adavosertib (Primary) ; Capecitabine (Primary) ; Sapitinib (Primary) ; Aspirin; Bevacizumab; Cetuximab; Fluorouracil; Irinotecan; Mitogen-activated protein kinase kinase inhibitors; MTOR protein inhibitors; Oxaliplatin; Panitumumab; Panitumumab; Phosphatidylinositol 3 kinase alpha inhibitors; Proto oncogene protein b raf inhibitors; Proto oncogene protein c-akt inhibitors
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms FOCUS4; FOCUS4-C; FOCUS4-N

    • Most Recent Events

    • 26 Jan 2022 Status changed from discontinued to completed.
    • 18 Sep 2021 Primary endpoint (FOCUS4-C Progression-free survival) has been met, according to Results published in the Journal of Clinical Oncology.
    • 18 Sep 2021 Results (n=247) assessing findings of FOCUS4-C, which tested the safety and efficacy of adavosertib in patients with RAS/TP53-mut mCRC compared with active monitoring (AM) and has achieved disease stability following induction chemotherapy, published in the Journal of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top